StockData
Immuneering Corp logo

Immuneering Corp (IMRX) stock

IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/30
$3.71+0.04 (+1.09%)

Close on Nov 13, 2026Market cap $240.27MP/E –Yield –

Immuneering price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Immuneering's price to sales ratio was 407.1× on Feb 28, 2023, against 48.9× a year earlier.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2023Feb 28, 2023407.1×+154.9
2022Dec 30, 2022252.2×+199.7
2021Dec 31, 202152.4×–

More Immuneering figures

See a number that looks wrong?